Current Osteoporosis Reports

, Volume 9, Issue 3, pp 160–166 | Cite as

Diagnostic Thresholds in Osteoporosis: How Are They Used in Clinical Trials?

  • Ronald C. Hamdy
  • Dustin M. Price
  • Miriam M. Mottl


Clinical trials are used to determine the efficacy and safety of a medication prior to approval for commercial use and to influence the prescribing habits of clinicians. The lack of uniformity in the diagnostic thresholds used in clinical trials on osteoporosis makes it difficult to compare the results of these trials. The use of placebo, different anatomical sites, T-score cutoff points, and risk factors precludes any meaningful comparison being made between the outcomes of clinical trials. Finally, the lack of uniform reporting format makes it difficult to retrieve important information to compare one medication to another. Because the diagnostic thresholds used affect the outcomes of these trials, health care providers need to be aware of these criteria to determine whether the results of a particular clinical trial can be applied to a particular patient.


Osteoporosis Randomized clinical trials Diagnostic thresholds Problems Evidence-based HIP VERT FIT BONE MORE PROOF 

Clinical Trial Acronyms


Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe


Fracture Intervention Trial


Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months


Hip Intervention Program


Health Outcomes and Reduced Incidence with Zoledronic Therapy


Multiple Outcomes of Raloxifene Evaluation


National Health and Nutrition Examination Survey


Prevent Recurrence of Osteoporosis Fracture


Vertebral Efficacy with Risedronate Therapy


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    • DeMets DL and Califf RM: A historical perspective on clinical trials innovation and leadership. JAMA 2011, 305(7):713–714. This article details the development of clinical research from its initial public health orientation to an industry-controlled business, often with little to no academic input. As this shift has occurred, trial methodologies have become increasingly influenced by imperatives to develop new approved products while meeting regulatory requirements. The authors call for renewed academic involvement in RCTs to adequately address public health needs in a profit-oriented system.Google Scholar
  2. 2.
    NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785–95.CrossRefGoogle Scholar
  3. 3.
    • Watts NB, Bilezikian JP, Camacho PM, et al.: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 2010, 16(Suppl 3). Detailed guidelines for the diagnosis and treatment of osteoporosis in clinical practice.Google Scholar
  4. 4.
    Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA. 2002;288:1889–97.PubMedCrossRefGoogle Scholar
  5. 5.
    Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002, 17:716–724.Google Scholar
  6. 6.
    O’Neill TW, Felsenberg D, Varlow J, et al. The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res. 1996;11:1010–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Liberman UA, Weiss SR, Brӧll J, et al. Effect of alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. NEJM. 1995;333:1437–43.PubMedCrossRefGoogle Scholar
  8. 8.
    Black DM, Palermo L, Nevitt MC, et al. Defining incident vertebral deformity: a prospective comparison of several approaches. J Bone Miner Res. 1999;14:90–101.PubMedCrossRefGoogle Scholar
  9. 9.
    Lunt M, Ismail AA, Felsenberg D, et al. Defining incident vertebral deformities in population studies: a comparison of morphometric criteria. Osteoporos Int. 2002;13:809–15.PubMedCrossRefGoogle Scholar
  10. 10.
    Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on Vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282:1344–52.PubMedCrossRefGoogle Scholar
  11. 11.
    Black DM, Cummings SR, Stone K, et al. A new approach to defining normal vertebral dimensions. J Bone Miner Res. 1991;6:883–92.PubMedCrossRefGoogle Scholar
  12. 12.
    Melton LJ, Kan SH, Frye MA, et al. Epidemiology of vertebral fractures in women. Am J Epidemiol. 1989;129:1000–11.PubMedGoogle Scholar
  13. 13.
    Smith-Bindman R, Cummings SR, Steiger P, et al. A comparison of morphometric definitions of vertebral fracture. J Bone Miner Res. 1991;6:25–34.PubMedCrossRefGoogle Scholar
  14. 14.
    Bonnick SL. Bone densitometry in clinical practice: application and interpretation. 2nd ed. Totowa: Humana; 2004.Google Scholar
  15. 15.
    Kanis JA, Melton III LJ, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137–41.PubMedCrossRefGoogle Scholar
  16. 16.
    Marshall T, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254–9.PubMedGoogle Scholar
  17. 17.
    Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:721–39.PubMedCrossRefGoogle Scholar
  18. 18.
    Von Mϋhlen D, Lunde AV, Barrett-Connor E, et al. Evaluation of the simple calculated osteoporosis risk estimation (SCORE) in older Caucasian women: the Rancho Bernardo study. Osteoporos Int. 1999;10:79–84.CrossRefGoogle Scholar
  19. 19.
    Ungar WJ, Josse R, Lee S, et al. The Canadian ScoreTM questionnaire. J Clin Densitom. 2000;3:269–80.PubMedCrossRefGoogle Scholar
  20. 20.
    Cadarette SM, Jaglal SB, Kreiger N, et al. Development and validation of the osteoporosis risk assessment instrument to facilitate selection of women for bone densitometry. CMAJ. 2000;162:1289–94.PubMedGoogle Scholar
  21. 21.
    Black DM, Steinbuch M, Palermo L, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int. 2001;12:519–28.PubMedCrossRefGoogle Scholar
  22. 22.
    Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med. 1995;332:767–73.PubMedCrossRefGoogle Scholar
  23. 23.
    Geusens P, Hochberg MC, Van Der Voort DJM, et al. Performance of risk indices for identifying low bone density in postmenopausal women. Mayo Clin Proc. 2002;77:629–37.PubMedCrossRefGoogle Scholar
  24. 24.
    Hochberg MC, Thompson DE, Ross PD. Validation of risk indices to identify postmenopausal women with an increased likelihood of osteoporosis. Osteoporos Int. 2002;13:S111.Google Scholar
  25. 25.
    Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385–97.PubMedCrossRefGoogle Scholar
  26. 26.
    Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241–9.CrossRefGoogle Scholar
  27. 27.
    Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with Raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282(7):637–45.PubMedCrossRefGoogle Scholar
  28. 28.
    Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med. 2000;109:267–76.PubMedCrossRefGoogle Scholar
  29. 29.
    Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. NEJM. 2001;344(19):1434–41.PubMedCrossRefGoogle Scholar
  30. 30.
    Reid DM, Hosking D, Kendler D, et al. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. Int J Clin Pract. 2008;62(4):575–84.PubMedCrossRefGoogle Scholar
  31. 31.
    Bonnick S, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over 2 years. J Clin Endocrinol Metab. 2006;91(7):2631–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005;20(1):141–51.PubMedCrossRefGoogle Scholar
  33. 33.
    Hosking D, Adami S, Felsenberg D, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomized, placebo-controlled study. Curr Med Res Opin. 2003;19(5):383–94.PubMedCrossRefGoogle Scholar
  34. 34.
    McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. NEJM. 2001;344(5):333–40.PubMedCrossRefGoogle Scholar
  35. 35.
    Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin. 2008;24(1):237–45.PubMedCrossRefGoogle Scholar
  36. 36.
    Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. NEJM. 2007;356(18):1809–22.PubMedCrossRefGoogle Scholar
  37. 37.
    • Cummings SR, Martin JS, McClung MR, et al.: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. NEJM 2009, 361:756–765. This article describes the FREEDOM trial, which randomly assigned osteoporotic women between the ages of 60 and 90 years to subcutaneous injections of 60 mg of denosumab or placebo twice yearly for a period of 3 years. The investigators concluded that this dosage of denosumab was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis.Google Scholar

Copyright information

© Springer Science+Business Media, LLC (outside the USA) 2011

Authors and Affiliations

  • Ronald C. Hamdy
    • 1
  • Dustin M. Price
    • 2
  • Miriam M. Mottl
    • 3
  1. 1.James H. Quillen College of MedicineEast Tennessee State UniversityJohnson CityUSA
  2. 2.James H. Quillen College of MedicineJohnson CityUSA
  3. 3.University of Rostock Medical SchoolRostockGermany

Personalised recommendations